Shake-up at FDA: New Leadership Following Recent Departures
FDA drug center head fired after commissioner's exit, replaced by Davis
The Economic Times
Image: The Economic Times
Tracy Beth Hoeg was dismissed as the acting head of the U.S. Food and Drug Administration's drug center, with Michael Davis appointed as her replacement. This change follows the exit of FDA Commissioner Marty Makary amid tensions with White House officials over drug approval decisions.
- 01Tracy Beth Hoeg announced her firing via social media, marking a significant leadership change at the FDA.
- 02Michael Davis, previously the deputy director of the Center for Drug Evaluation and Research, has taken over as acting director.
- 03The FDA has experienced substantial staff turnover since President Donald Trump's administration began, losing thousands of employees.
- 04Karim Mikhail has been appointed as the acting director of the Center for Biologics Evaluation and Research, following the departure of Vinay Prasad.
- 05Hoeg's tenure included controversial views on COVID vaccines and efforts to revise the childhood vaccination schedule.
Advertisement
In-Article Ad
Tracy Beth Hoeg was fired from her position as the acting head of the U.S. Food and Drug Administration's (FDA) drug center on Friday, with Michael Davis stepping in as her replacement. This leadership change comes shortly after the departure of FDA Commissioner Marty Makary, who faced criticism and clashes with White House and health advisers regarding drug approval decisions. Under the new administration, the FDA is undergoing significant restructuring, having lost thousands of employees since President Donald Trump's tenure began. Alongside Davis's appointment, Karim Mikhail has been named the acting director of the Center for Biologics Evaluation and Research, succeeding Vinay Prasad. Hoeg's tenure was marked by her controversial stance on COVID vaccines and her involvement in an initiative to reduce the number of recommended childhood vaccinations, which is currently on hold due to legal challenges. The White House continues to implement changes in top health positions, aiming to tighten control over the agency's operations.
Advertisement
In-Article Ad
The leadership changes at the FDA may influence drug approval processes and public health policies, potentially affecting healthcare providers and patients.
Advertisement
In-Article Ad
Reader Poll
Should the FDA prioritize revising childhood vaccination schedules?
Connecting to poll...
More about U.S. Food and Drug Administration
Read the original article
Visit the source for the complete story.